Ascento-CDA is developing and will soon launch a solution, which by use of OCT scans seek to detect 65+ people at early stages of cognitive decline, diabetes and other age-related diseases and support remediation strategies. Its technology encapsulates data analysis and highly sensitive Cytokine tests, incorporated in algorithmic analysis, which allows us to issue Actionable Intelligence to enhance Healthy Aging. Ascento-CDA performed a first IRB with a clinic in New York and will now start an IRB study, which includes OCT scans, Cytokine testing and cognitive decline data. Vision is to capture a share of the 15 million OCT scans performed in the US and funnel them to our IICM technology, allowing them to identify cognitive – and other - conditions, related to age.